Pharmacological correction of experimentally induced osteoporosis complicated by type 2 diabetes mellitus
- Authors: Bairamov A.A.1,2, Mamina N.S.2, Karonova T.L.1, Simanenkova A.V.1, Kozhyurin M.V.2, Kosyakova G.P.2, Shabanov P.D.2
-
Affiliations:
- Almazov National Medical Research Centre
- Institute of Experimental Medicine
- Issue: Vol 22, No 1 (2024)
- Pages: 75-80
- Section: Original study articles
- URL: https://journal-vniispk.ru/RCF/article/view/258602
- DOI: https://doi.org/10.17816/RCF623110
- ID: 258602
Cite item
Abstract
BACKGROUND: Osteoporosis remains one of the most important medical problems worldwide with significant economic consequences. The development of new drugs based on unique biologically active compounds can contribute significantly to osteoporosis management.
AIM: To evaluate the osteogenesis processes by evaluating bone-remodeling markers in the blood serum during the treatment of experimental osteoporosis complicated by type 2 diabetes mellitus.
MATERIALS AND METHODS: The study was performed on an experimental model of osteoporosis, followed by the induction of type 2 diabetes mellitus, using biochemical methods to analyze markers of osteoporosis in the blood serum.
RESULTS: The results of the analysis of bone remodeling markers revealed that the antiosteoporotic activity of a composite preparation based on succinic acid salts is dependent on glucose metabolism disorders such as diabetes mellitus. The high efficacy of the new drug in monotherapy and combination with vitamin D3 in the activation of osteogenesis in experimental osteoporosis was balanced by impaired metabolic processes in type 2 diabetes mellitus.
CONCLUSIONS: The results indicate the dependence of the pharmacological effectiveness of the antiosteoporosis agent on metabolic disorders, such as type 2 diabetes mellitus, in female rats with experimental osteoporosis.
Full Text
##article.viewOnOriginalSite##About the authors
Alekber A. Bairamov
Almazov National Medical Research Centre; Institute of Experimental Medicine
Author for correspondence.
Email: alekber@mail.ru
ORCID iD: 0000-0002-0673-8722
SPIN-code: 9802-9988
MD, Dr. Sci. (Medicine)
Russian Federation, Saint Petersburg; Saint PetersburgNailya Sh. Mamina
Institute of Experimental Medicine
Email: nelya-mamina@yandex.ru
Russian Federation, Saint Petersburg
Tatiana L. Karonova
Almazov National Medical Research Centre
Email: karonova@mail.ru
ORCID iD: 0000-0002-1547-0123
SPIN-code: 3337-4071
MD, Dr. Sci. (Medicine)
Russian Federation, Saint PetersburgAnna V. Simanenkova
Almazov National Medical Research Centre
Email: annasimanenkova@mail.ru
ORCID iD: 0000-0003-3300-1280
SPIN-code: 3675-9216
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgMikhail V. Kozhyurin
Institute of Experimental Medicine
Email: ssrkog@mail.ru
Russian Federation, Saint Petersburg
Galina P. Kosyakova
Institute of Experimental Medicine
Email: galkos1@mail.ru
ORCID iD: 0000-0001-7211-7839
SPIN-code: 9987-7041
Cand. Sci. (Biology)
Russian Federation, Saint PetersburgPetr D. Shabanov
Institute of Experimental Medicine
Email: pdshabanov@mail.ru
ORCID iD: 0000-0003-1464-1127
SPIN-code: 8974-7477
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint PetersburgReferences
- Lesnyak OM. Osteoporosis audit in the Russian Federation. Preventive Medicine. 2011;(2):7–10. (In Russ.) EDN: PUGUSZ
- Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporosis Int. 2000;11(7):556–561. doi: 10.1007/s001980070075
- Kulakov VI, Savelieva GM, Manukhin IB. editors. Gynecology. National guide. Moscow: GEOTAR-Media; 2009. 670 p. (In Russ.)
- Riggz BL, Melton D. Osteoporosis. Etiology, diagnosis, treatment. Moscow: Binom; 2000. P. 309–313. (In Russ.)
- Kondrashova MN, Dynnik VV, Kaminsky YG, et al. editors. Mitochondrial processes in the temporal organization of life activity. 1978. 182 p. (In Russ.)
- Mayevsky EI, Grishina EV, Haustova YaV, et al. Once again about drugs containing succinate. Gastroenterology of St. Petersburg. 2017;(1):91–92. (In Russ.) EDN: YRHBUZ
- Vasilieva AA, Simonova MA, Bairamov AA, et al. Correction of the functional state of female rats after unilateral ovariectomy using a succinate containing composition. Cardiometry. 2017;(10):86–92. EDN: YPOTOX doi: 10.12710/cardiometry.2017.8692
- Bairamov AA, Maevskii EI, Shabanov PD. Correction of bone remodeling in experimental osteoporosis. Reviews on Clinical Pharmacology and Drug Therapy. 2019;17(4):43–50. (In Russ.) EDN: MZRJFH doi: 10.17816/RCF17443-50
- Lisovsky DA, Mamina NSh, Droblenkov AV, et al. Morphological and biochemical characteristics of osteogenesis during drug therapy for experimental osteoporosis. Translational Medicine. 2023;10(6): 535–548. EDN: LOUQMK doi: 10.18705/2311-4495-2023-10-6-535-548
- Wallander M, Axelsson KF, Nilsson AG, et al. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly: A study from the fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res. 2017;32(3):449–460. doi: 10.1002/jbmr.3002
- Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the women’s health initiative observational study. J Clin Endocrinol Metab. 2006;91(9):3404–3410. doi: 10.1210/jc.2006-0614.
- Levitsky AP, Makarenko OA, Denga OV, et al. Experimental methods of osteogenesis stimulators research: Methodical recommendations. Kiev: Avicenna; 2005. С. 31–38. (In Russ.)
- Frolkis VV, Povorozniuk VV, Evtushenko OA, Grigorieva NV. Experimental osteoporosis. Doctor. 2003;(6):48–52. (In Russ.)
- Bairamov AA, Mamina NSH, Karonova TL, Shabanov PD. Possibilities of in vivo validation of a model of experimental osteoporosis. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(4): 365–367. (In Russ.) EDN: OUJNZD doi: 10.7816/RCF184365-367
- Bayrasheva VK, Babenko AY, Dobronravov VA, et al. Uninephrectomized high-fat-fed nicotinamide-streptozotocininduced diabetic rats: A model for the investigation of diabetic nephropathy in type 2 diabetes. J Diabetes Res. 2016;2016:8317850. doi: 10.1155/2016/8317850
- Simanenkova A, Minasian S, Karonova T, et al. Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance. Sci Rep. 2021;11(1):6700. doi: 10.1038/s41598-021-86132-2
- Тimkina NV, Semenova NY, Simanenkova AV, et al. Modern glucose-lowering treatment effect on bone remodeling in experimental diabetes mellitus and surgical menopause. Diabetes Mellitus. 2023;26(2):145–156. (In Russ.) EDN: QWCBWH doi: 10.14341/DM12967
- Cao B, Li R, Tian H, et al. Effect on glycemia in rats with type 2 diabetes induced by streptozotocin: low-frequency electro-pulse needling stimulated Weiwanxiashu (EX-B3) and Zusanli (ST 36). J Tradit Chin Med. 2016;36(6):768–778. doi: 10.1016/s0254-6272(17)30013-4
- Patent RU 2582973/04.03.24. Byul. No. 34. Bairamov AA, Shabanov PD, Maevskii EI, et al. Anti-osteoporosis drug. Available from: https://yandex.ru/patents/doc/RU2582973C1_20160427 (In Russ.)
- Bairamov AA, Mamina NSh, Lisovskiy DA, et al. Evaluation of osteogenesis processes against the background of experimental osteoporosis therapy. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(3):273–282. (In Russ.) EDN: BYNUCG doi: 10.17816/RCF567788
